MRK
Another green light for Merck
Merck just added a new badge to its growing “pipeline actually matters” collection: the European Commission approved ENFLONSIA (clesrovimab) for preventing RSV lower respiratory tract disease in infants during their first RSV season.
Why investors should care
RSV is one of those nasty seasonal bugs that can turn a normal winter into a hospital drama, especially for babies. So this isn’t just a headline about paperwork — it’s a shot at a real commercial opportunity in a market where parents, doctors, and health systems are willing to pay for prevention.
The money angle
For Merck, every approval like this helps diversify the story beyond its blockbuster but aging core businesses. If ENFLONSIA gets traction in Europe, it could become another revenue stream that smooths out the inevitable “what happens when the old cash cows slow down?” question.
Big picture
This is the kind of update biotech and pharma investors love: regulatory win first, sales pitch second. The next thing to watch is rollout — because approvals are nice, but prescriptions are what actually make the stock smile.